Precision Neuroscience is an American brain–computer interface (BCI) company based in New York City and with offices in Mountain View, California, Addison, Texas and Minneapolis, Minnesota.
[1] Precision Neuroscience was founded by Benjamin Rapoport, Michael Mager, Demetrios Papageorgiou, and Mark Hettick and was launched in 2021.
[3] Rapoport is a neurosurgeon in the Mount Sinai Health System in New York City, where he specializes in minimally invasive surgery.
In January 2023, the company raised a $41 million Series B funding round led by Forepont Capital Partners.
[7] Precision Neuroscience has successfully used the Layer 7 Cortical Interface to record neural signals in animals and in human patients.
According to WIRED, “the implants were able to read, record, and map electrical activity in part of the patients’ temporal lobes, which helps process sensory input.”[11] In May 2023, the U.S. Food and Drug Administration granted Precision Neuroscience's system Breakthrough Device designation.